Characteristic | Percentage (%)/Median (range) | |
---|---|---|
Age (years) | 62.7 | (32–85) |
Baseline CA-125 level (U/mL) | 725 | (14–26,190) |
Nadir CA-125 level (U/mL) | 10 | (6–35) |
CA-125 level at relapse (U/mL) | 124 | (32–5528) |
Histology | ||
 High grade Serous | 104 | (73.2) |
 High grade Endometrioid | 26 | (18.3) |
 Undifferentiated | 9 | (6.3) |
Malignant mixed müllerian tumor | 3 | (2.1) |
Surgical residual of initial CRS | ||
 < 1 cm | 88 | (62.0) |
 1–2 cm | 5 | (3.5) |
 > 2 cm | 28 | (19.7) |
 Unknown | 21 | (14.8) |
FIGO stage | ||
 I | 10 | (7.0) |
 II | 11 | (7.7) |
 III | 95 | (63.6) |
 IV | 20 | (14.1) |
 Unknown | 6 | (4.2) |
NAC | 92 | (63.4) |
SNAC | 55 | (38.7) |
BRCA mutations | 5 | (22.7) |
Avastin® at recurrence | 44 | (31.0) |